Loxo signs lucrative cancer drug deal with Bayer, but shares fall

(Reuters) – Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany’s Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply